Literature DB >> 26267704

Idiopathic Acute Transverse Myelitis in Children: A Retrospective Series.

Spencer C H Kuo1, Wan-Hua Cho1, Hsin-I Shih2, Yi-Fang Tu3.   

Abstract

OBJECTIVE: Acute transverse myelitis (ATM) is a focal inflammatory disorder of the spinal cord, resulting in motor, sensory, and autonomic dysfunction. In this study, we delineate the clinical manifestations, neuroimaging characteristics, and outcome-associated risk factors in children with idiopathic ATM.
METHODS: We retrospectively reviewed the medical charts and neuroimages in nine children aged younger than 18 years diagnosed with ATM between January 2006 and August 2014.
RESULTS: The mean onset age was 5 years and 9 months. Infectious prodromes were observed in six patients. Leg weakness was observed in all patients, autonomic sphincter dysfunction was observed in seven patients, and sensory deficits on admission were observed only in four patients. The diagnosis was delayed in patients younger than 5.5 years compared with older children. The adverse outcomes cannot be predicted by the course of the disease, the laboratory findings, nor the extent of magnetic resonance imaging-detected spinal lesions; however, these outcomes can be predicted by poor early response to corticosteroids and the requirement of additional treatments (p < 0.05).
CONCLUSION: The diagnosis of ATM is challenging in young children. Children with ATM who responded early to corticosteroids had more favorable outcomes than those who required additional therapies. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 26267704     DOI: 10.1055/s-0035-1558436

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  1 in total

1.  Transverse myelitis masquerading as cauda equina syndrome, stroke and cervical myelopathy.

Authors:  Sally Shin Jie Chan; Arun-Kumar Kaliya-Perumal; Quan You Yeo; Jacob Yoong Leong Oh
Journal:  Biomedicine (Taipei)       Date:  2020-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.